Drug Metabolism in Diabetic Subjects with Fatty Livers
Overview
Affiliations
The effect of fatty degeneration of liver parenchyma on drug metabolism was investigated in 21 obese non-insulin-dependent diabetic subjects by measuring plasma antipyrine kinetics, hepatic cytochrome P-450, liver size and the extent of fatty infiltration. The hepatic drug metabolising capacity, as measured by total antipyrine clearance and the estimated total amount of cytochrome P-450, was at the same level as in non-diabetic control subjects with normal livers. Relative antipyrine clearance (per unit weight of liver) and cytochrome P-450 concentrations were significantly lower in the diabetics than in controls. The extent of fatty infiltration correlated poorly with the indices of drug metabolism. In non-insulin-dependent diabetics, slight to moderate hepatic fatty infiltration, without more serious structural distortion interfering with hepatic blood flow or hepatocellular function, seems to have only a minor influence on drug metabolism.
Lenoir C, Rollason V, Desmeules J, Samer C Front Pharmacol. 2021; 12:733935.
PMID: 34867341 PMC: 8637893. DOI: 10.3389/fphar.2021.733935.
Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.
Dostalek M, Akhlaghi F, Puzanovova M Clin Pharmacokinet. 2012; 51(8):481-99.
PMID: 22668340 DOI: 10.2165/11631900-000000000-00000.
Body mass index and the efficacy of acid-mediating agents for GERD.
Jacobson B Dig Dis Sci. 2008; 53(9):2313-7.
PMID: 18629639 DOI: 10.1007/s10620-008-0414-8.
Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver.
Piao Y, Li J, Shi Y World J Gastroenterol. 2003; 9(11):2612-5.
PMID: 14606109 PMC: 4656553. DOI: 10.3748/wjg.v9.i11.2612.
Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.
OConnor P, Feely J Clin Pharmacokinet. 1987; 13(6):345-64.
PMID: 3325214 DOI: 10.2165/00003088-198713060-00001.